Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML

April 24, 2026 8:00 AM

Kyowa Kirin Co., Ltd. (TSE: 4151) and Kura Oncology, Inc. (NASDAQ: KURA) announced the first patient has been dosed in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found